User:Pradaxacost

The search for a modest molecule, orally administered drug, Boehringer Ingelheim started in 1992 around the basis with the framework from the peptide thrombin inhibitor N -a-(2-Naphthylsulfonylglycyl)-4-amidinophenylalaninpiperidin (a-NAPAP). Commencing from a triple-substituted benzimidazole as being a framework, [11], the molecule was steadily optimal conformation and affinity for binding to thrombin approximated. The resulting hugely polar and consequently poorly absorbable dabigatran was the introduction of two safeguarding groups (esterified carboxyl group and O - n -hexyl carbamate ) modified to ensure that it's orally bioavailable enough. "Etexilate" is actually a portmanteau with the two reactants ethanol and hexanoic acid. From 1996, the anticoagulant effect of dabigatran was in vitro and in animal designs studied, the clinical reports began in the late 1990s. In March 2008, pradaxa costs by the European Commission accepted for the European industry, in August 2011 was followed by the approval with the expansion of indications.